// App-Quantinova.ai

e20041 : Maintenance (MT) treatment (Tx) after lenalidomide, bortezomib, and dexamethasone (RVD) induction and stem cell transplant (SCT) in high-risk (HR) patients (pts) with newly diagnosed multiple myeloma (NDMM): A real-world analysis.

Researchers

Presenter

  • Rafael Fonseca

Principal Investigators

  • Kejal Parikh

  • Brian Ung

  • Quanhong Ni

  • Amit Agarwal

Medical Centers

  • Mayo Clinic, Phoenix, AZ

  • Celgene Corporation, Summit, NJ

Locations

  • United States

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • Bortezomib

  • Techniclone TNT

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved